#United States #Florida Cancer Specialists #Fort Myers #Oncology Care #COA 2026

Florida Cancer Specialists Leaders Present Innovative Solutions at COA 2026 Conference

The Florida Cancer Specialists & Research Institute, LLC (FCS) has taken a significant step forward in leading the transformation of community oncology care. During the recent Community Oncology Alliance (COA) 2026 Conference, key leaders from FCS showcased innovative practices aimed at improving cancer care delivery across the state of Florida. This event gathered prominent industry stakeholders to discuss vital elements impacting community oncology from clinical to operational facets.

Dr. David Wenk, the Assistant Managing Physician at FCS, emphasized the organization's commitment to anticipating patient and provider needs. He stated, "At FCS, our focus has always been on anticipating the needs of our patients and providers and responding with thoughtful, forward-looking solutions." By evolving the care delivery model, FCS aims to enhance outcomes for cancer patients who rely on community services.

During the conference, various FCS leaders took to the stage to share their insights and expertise on multiple topics:

• - Dr. Ameet Patel, Director of Cell Therapy, introduced the topic "CAR T Comes to Main Street: Expanding Access, Empowering Care" which focused on advancing access to cutting-edge CAR T-cell therapy in community settings.
• - Dr. Richard McDonough, Director of Advocacy and Policy, provided a series of presentations addressing first-year insights after fellowship and collaborated on wrap-up discussions, highlighting the shared experiences and reflections from the conference.
• - Dr. Jeanine Ewing, Clinical Oncology Pharmacist at FCS, discussed "Communication in Action: Empowering Community Oncology Pharmacists to Optimize Prostate Cancer Care Across Urology and Oncology," showcasing the critical role of pharmacists in enhancing patient care strategies.
• - Dr. Lucio N. Gordan, President and Managing Physician, delivered insights on the importance of quality in community oncology through presentations like "The Quality of Community Oncology" and introduced various innovative solutions that focus on operational efficiencies.
• - Dr. Bradley Monk, Medical Director of Late-Phase Clinical Research, tackled the topic of expanding clinical trial access using tech tools to reinforce strategies that benefit community oncology practices.

Ryan Ciarrocchi, Chief Executive Officer of FCS, articulated the ongoing dedication to improving community-based cancer care. He stated, "As the future of oncology continues to evolve, FCS remains committed to working alongside leading providers nationwide to share best practices, advance innovation, and reinforce a patient-centered approach to community-based cancer care."

FCS has excelled in innovation within the oncology sector for over four decades, establishing itself as a leader in clinical research programs. The robust structure includes a partnership with the Sarah Cannon Research Institute and advanced clinical trial matching technology that ensures patients have access to the latest therapies right in their communities. With over 180 active clinical trials annually, FCS directly contributes to improving patient outcomes and accelerating progress in oncology. Notably, many drugs approved by the FDA were first made available to patients at FCS via clinical trials, illustrating the institute's significant role in oncology advancements.

In summary, the COA 2026 Conference served as a platform for Florida Cancer Specialists to exhibit their commitment to innovation, collaboration, and quality care in community oncology. As FCS continues to strengthen this model of care, patients can anticipate better outcomes and enhanced access to cancer treatments.

For more information about FCS and its offerings, visit FLCancer.com.